James A. De Lemos

James A. De Lemos's AcademicInfluence.com Rankings

James A. De Lemos

Philosophy

#5791

World Rank

#8691

Historical Rank

Logic

#3006

World Rank

#4098

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is James A. De Lemos Influential?

(Suggest an Edit or Addition)

(See a Problem?)

James A. De Lemos's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (4204)
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (2552)
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (1864)
TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy (2000) (1462)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. (2004) (1346)
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (1334)
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. (2001) (1140)
HDL cholesterol efflux capacity and incident cardiovascular events. (2014) (1102)
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. (2011) (1065)
Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. (2010) (1035)
2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infa (2016) (866)
A sensitive cardiac troponin T assay in stable coronary artery disease. (2009) (827)
Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide (2002) (756)
Third universal definition of myocardial infarction. (2012) (751)
Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study (2011) (700)
Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. (2010) (696)
Race and gender differences in C-reactive protein levels. (2005) (556)
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. (2012) (538)
Benchmarks for the Assessment of Novel Cardiovascular Biomarkers (2007) (511)
2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) (485)
Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction: A TIMI 14 Substudy (2001) (465)
Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes (2003) (460)
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. (2003) (454)
Prevalence and Determinants of Troponin T Elevation in the General Population (2006) (425)
Soluble CD40L: Risk Prediction After Acute Coronary Syndromes (2003) (409)
Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results From the Dallas Heart Study (2005) (401)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. (2008) (355)
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. (2004) (353)
Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults (2012) (341)
Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. (2004) (333)
ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. (2001) (303)
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial (2006) (302)
Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. (2014) (296)
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. (2013) (293)
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. (2000) (289)
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. (2011) (288)
Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. (2008) (287)
Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. (2004) (281)
Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. (2000) (250)
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. (2001) (250)
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. (2005) (229)
ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. (2000) (225)
Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). (2011) (224)
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. (2004) (222)
Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. (2015) (216)
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. (2009) (211)
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. (2004) (208)
The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. (2014) (205)
Dose–Response Relationship Between Physical Activity and Risk of Heart Failure: A Meta-Analysis (2015) (196)
A 4-Tiered Classification of Left Ventricular Hypertrophy Based on Left Ventricular Geometry: The Dallas Heart Study (2010) (191)
Cardiorespiratory Fitness and Classification of Risk of Cardiovascular Disease Mortality (2011) (190)
Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes (2006) (190)
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. (2008) (187)
Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. (2017) (187)
Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. (2017) (184)
Left atrial structure and function and clinical outcomes in the general population. (2013) (184)
Relationship Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study (2005) (183)
Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. (2002) (179)
The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. (2007) (177)
Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). (2007) (177)
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. (2007) (166)
Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. (2000) (163)
Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. (2006) (155)
Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. (2007) (152)
Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. (2020) (152)
Continuous Dose-Response Association Between Sedentary Time and Risk for Cardiovascular Disease: A Meta-analysis. (2016) (150)
Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. (2013) (149)
Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury (2019) (147)
Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study. (2011) (143)
Myocarditis Temporally Associated with COVID-19 Vaccination. (2021) (142)
Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. (2012) (141)
Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study. (2015) (140)
Relation of Regional Fat Distribution to Left Ventricular Structure and Function (2013) (140)
Sex differences in the relationship between C-reactive protein and body fat. (2009) (140)
Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. (2011) (139)
Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension (2015) (132)
Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. (2004) (129)
Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. (2000) (128)
Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. (2013) (127)
Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease (2012) (127)
High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure: MESA (Multi-Ethnic Study of Atherosclerosis) (2017) (125)
Interleukin-18, the Metabolic Syndrome, and Subclinical Atherosclerosis: Results From the Dallas Heart Study (2007) (123)
Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium (2019) (118)
Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease: Results From the Cooper Center Longitudinal Study (2018) (118)
High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. (2019) (117)
Association of Cystatin C With Left Ventricular Structure and Function: The Dallas Heart Study (2009) (114)
Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. (2012) (114)
Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. (2007) (112)
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors: Results From the Dallas Heart Study (2009) (111)
Body fat distribution and incident cardiovascular disease in obese adults. (2013) (111)
A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 (2006) (110)
Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). (2010) (109)
Brain Natriuretic Peptide Measurement in Acute Coronary Syndromes: Ready for Clinical Application? (2002) (109)
Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. (1996) (106)
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. (2000) (103)
Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. (2011) (102)
Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. (2015) (100)
Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study (2005) (100)
Sex-Based Differences in Cardiometabolic Biomarkers (2017) (100)
Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. (2009) (99)
Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension (2015) (98)
Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. (2013) (97)
Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic (2021) (95)
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. (2001) (92)
Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock: Findings From the NCDR. (2016) (91)
Same-day discharge after percutaneous coronary intervention: a meta-analysis. (2013) (89)
The search for a biomarker of cardiac ischemia. (2003) (88)
Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. (2017) (88)
Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction. (2012) (87)
Left Ventricular Hypertrophy, Subclinical Atherosclerosis, and Inflammation (2007) (86)
Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. (2013) (84)
Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. (2015) (83)
Association of cardiorespiratory fitness with left ventricular remodeling and diastolic function: the Cooper Center Longitudinal Study. (2014) (83)
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). (2007) (82)
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. (2007) (80)
Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: the Cooper Center Longitudinal Study. (2015) (80)
Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. (2003) (79)
Use and misuse of cardiac troponins in clinical practice. (2007) (79)
Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. (2002) (79)
Mild hyponatremia is associated with an increased risk of death in an ambulatory setting. (2013) (78)
Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). (2005) (78)
Body size misperception: a novel determinant in the obesity epidemic. (2010) (78)
HDL cholesterol: physiology, pathophysiology, and management. (2007) (77)
In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine (2021) (77)
Association between cardiorespiratory fitness and accelerometer-derived physical activity and sedentary time in the general population. (2014) (76)
Homoarginine and Cardiovascular Outcome in the Population-Based Dallas Heart Study (2014) (74)
Plasma Osteoprotegerin Levels in the General Population: Relation to Indices of Left Ventricular Structure and Function (2007) (73)
Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. (2016) (71)
Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis (2009) (71)
Cost-Related Medication Nonadherence in Adults With Atherosclerotic Cardiovascular Disease in the United States, 2013 to 2017. (2019) (69)
Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. (2008) (69)
Association of Out-of-Pocket Annual Health Expenditures With Financial Hardship in Low-Income Adults With Atherosclerotic Cardiovascular Disease in the United States (2018) (69)
Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study. (2015) (66)
Management of perioperative myocardial infarction in noncardiac surgical patients. (2006) (66)
Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts (2017) (66)
Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. (2008) (65)
Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. (2013) (65)
Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: A Meta-Analysis of Population-Based Studies Involving 17,180 Individuals. (2019) (65)
Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD). (2019) (64)
Elevated troponin I levels in acute liver failure: Is myocardial injury an integral part of acute liver failure? (2007) (63)
Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study). (2015) (63)
Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy (2017) (62)
Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. (2007) (62)
Relationship between Perceptions about Neighborhood Environment and Prevalent Obesity: Data from the Dallas Heart Study (2012) (61)
The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. (2002) (61)
Coronary Artery Calcium Improves Risk Classification in Younger Populations. (2015) (60)
Cardiovascular risk indicators and perceived race/ethnic discrimination in the Dallas Heart Study. (2008) (59)
Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II. (2000) (58)
Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD. (2015) (57)
Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. (2003) (57)
Inaccuracy of Estimated Resting Oxygen Uptake in the Clinical Setting (2014) (57)
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. (2011) (56)
Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. (2007) (56)
Symmetrical Dimethylarginine Predicts Mortality in the General Population: Observations From the Dallas Heart Study (2013) (56)
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. (2010) (56)
A change in serum myoglobin to detect acute myocardial infarction in patients with normal troponin I levels. (2004) (56)
Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). (2008) (56)
The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR (2017) (54)
Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. (2015) (54)
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. (2004) (53)
Highly sensitive troponin assays and the cardiology community: a love/hate relationship? (2011) (53)
Diabetes Mellitus and Trends in Hospital Survival After Myocardial Infarction, 1994 to 2006: Data From the National Registry of Myocardial Infarction (2012) (53)
Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review (2015) (53)
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). (2011) (52)
The relationship between C-reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study. (2012) (52)
The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database. (2016) (52)
Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. (2018) (52)
Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. (2004) (51)
Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. (2008) (51)
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. (2001) (51)
Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study (2011) (50)
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. (2008) (50)
Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. (2012) (49)
Fitness in Young Adulthood and Long-Term Cardiac Structure and Function: The CARDIA Study. (2017) (49)
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US (2021) (47)
Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population. (2015) (47)
High-Sensitivity Cardiac Troponin I Assay to Screen for Acute Rejection in Patients With Heart Transplant (2014) (46)
Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. (2009) (46)
Clinical trial participation after myocardial infarction in a national cardiovascular data registry. (2014) (46)
Differential Associations Between Soluble Cellular Adhesion Molecules and Atherosclerosis in the Dallas Heart Study: A Distinct Role for Soluble Endothelial Cell-Selective Adhesion Molecule (2009) (46)
Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. (2004) (45)
Comparison of Readmission Rates After Acute Myocardial Infarction in 3 Patient Age Groups (18 to 44, 45 to 64, and ≥65 Years) in the United States. (2017) (45)
Coronary artery calcification and family history of myocardial infarction in the Dallas heart study. (2014) (45)
Contemporary Epidemiology of Heart Failure in Fee-For-Service Medicare Beneficiaries Across Healthcare Settings (2017) (45)
Racial Differences in Cardiovascular Biomarkers in the General Population (2019) (44)
Relation of troponin elevation to outcome in patients with infective endocarditis. (2008) (44)
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. (2015) (44)
Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease:the Dallas Heart Study. (2010) (44)
Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis (2022) (44)
Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. (2006) (44)
Multiple biomarker panels for cardiovascular risk assessment. (2008) (43)
Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. (2004) (43)
Amino-terminal pro-B-type natriuretic peptides: testing in general populations. (2008) (42)
Prediction of 30-Year Risk for Cardiovascular Mortality by Fitness and Risk Factor Levels: The Cooper Center Longitudinal Study (2014) (42)
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. (2020) (42)
Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. (2009) (42)
Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non–ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry–Get with the Guideli (2016) (41)
The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: Observations from the Dallas Heart Study. (2009) (41)
Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines–Heart Failure Program (2017) (41)
Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. (2010) (40)
Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. (2001) (40)
Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry). (2014) (40)
Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator (2018) (40)
Regional Fat Distribution and Blood Pressure Level and Variability: The Dallas Heart Study (2016) (39)
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). (2008) (38)
Factors Associated With Left Atrial Remodeling in the General Population (2017) (38)
Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. (2000) (38)
Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPARγ agonism (2006) (38)
Time is muscle in primary PCI: the strength of the evidence grows. (2004) (37)
Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. (2020) (37)
Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. (2003) (37)
Implications of family history of myocardial infarction in young women. (2007) (37)
Intraosseous versus intravenous access in patients with out-of-hospital cardiac arrest: Insights from the resuscitation outcomes consortium continuous chest compression trial. (2019) (37)
American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines (2020) (37)
Relation of Adiponectin to All-Cause Mortality, Cardiovascular Mortality, and Major Adverse Cardiovascular Events (from the Dallas Heart Study). (2016) (36)
Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. (2002) (36)
Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study. (2010) (36)
Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. (2019) (36)
Biomarkers and cardiovascular disease: determining causality and quantifying contribution to risk assessment. (2009) (36)
Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. (2018) (36)
Intensive Care Utilization in Stable Patients With ST-Segment Elevation Myocardial Infarction Treated With Rapid Reperfusion. (2019) (35)
Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction. (2006) (35)
Effect of Exercise and Pharmacological Interventions on Visceral Adiposity: A Systematic Review and Meta‐analysis of Long‐term Randomized Controlled Trials (2019) (35)
Role of Hospital Volumes in Identifying Low-Performing and High-Performing Aortic and Mitral Valve Surgical Centers in the United States (2017) (35)
High-Sensitivity Troponin T and Cardiovascular Events in Systolic Blood Pressure Categories: Atherosclerosis Risk in Communities Study (2015) (35)
Association of cardiac troponin I with disease severity and outcomes in patients with pulmonary hypertension. (2013) (35)
Association of the New Peer Group–Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program (2019) (35)
Relation of family history of myocardial infarction and the presence of coronary arterial calcium in various age and risk factor groups. (2007) (34)
Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. (2010) (34)
Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events (2017) (34)
Impact of Chronic Total Occlusions and Coronary Revascularization on All-Cause Mortality and the Incidence of Ventricular Arrhythmias in Patients With Ischemic Cardiomyopathy. (2015) (34)
Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. (2015) (34)
Association between number of live births and markers of subclinical atherosclerosis: The Dallas Heart Study (2014) (34)
Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study (2019) (33)
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome. (2009) (33)
Association of prediabetes by fasting glucose and/or haemoglobin A1c levels with subclinical atherosclerosis and impaired renal function: Observations from the Dallas Heart Study (2014) (32)
Association between Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios and Coronary Artery Calcification Score among Asymptomatic Patients: Data from a Cross-Sectional Study (2019) (32)
Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Regis (2017) (31)
Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. (2008) (31)
Perceived lifetime risk for cardiovascular disease (from the Dallas Heart Study). (2014) (31)
Amino-terminal pro-B-type natriuretic peptides in stable and unstable ischemic heart disease. (2008) (31)
Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. (2008) (31)
Fracture and embolization of an inferior vena cava filter strut leading to cardiac tamponade. (2009) (30)
Evaluation of a Novel Rule-Out Myocardial Infarction Protocol Incorporating High-Sensitivity Troponin T in a US Hospital. (2018) (30)
Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non–ST-Segment Elevation Myocardial Infarction (2017) (30)
Newer biomarkers in heart failure. (2009) (30)
Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines–Heart Failure Registry (2018) (29)
Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. (2012) (29)
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial (2010) (29)
Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. (2010) (29)
Ascending Aortic Dimensions in Former National Football League Athletes (2017) (29)
Methodologic and Clinical Validation of the TIMI Myocardial Perfusion Grade in Acute Myocardial Infarction (2002) (29)
Systems-Based Improvement in Door-to-Balloon Times at a Large Urban Teaching Hospital: A Follow-Up Study From Parkland Health and Hospital System (2009) (28)
Association of Galectin-3 with Diabetes Mellitus in the Dallas Heart Study. (2019) (27)
Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries. (2020) (27)
Association between neighborhood‐level socioeconomic deprivation and incident hypertension: A longitudinal analysis of data from the Dallas heart study (2018) (27)
Impact of Smoking on Circulating Cardiac Troponin I Concentrations and Cardiovascular Events in the General Population: The HUNT Study (Nord-Trøndelag Health Study) (2016) (27)
Dynamic Relation of Changes in Weight and Indices of Fat Distribution With Cardiac Structure and Function: The Dallas Heart Study (2017) (26)
Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19 (2020) (26)
Urinary tract infection in patients with acute coronary syndrome: a potential systemic inflammatory connection. (2004) (26)
“Malignant” Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi‐Ethnic Study of Atherosclerosis) (2018) (26)
Statins for acute coronary syndrome. (2011) (25)
Application of the screening for Heart Attack Prevention and Education Task Force recommendations to an urban population: observations from the Dallas Heart Study. (2008) (25)
Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. (2002) (25)
Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy. (2000) (25)
Atherosclerotic Cardiovascular Disease Prevention: A Comparison Between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines (2014) (25)
Interactions Between Smoking, Pulmonary Surfactant Protein B, and Atherosclerosis in the General Population: The Dallas Heart Study (2011) (25)
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). (2016) (25)
Burden of Catastrophic Health Expenditures for Acute Myocardial Infarction and Stroke Among Uninsured in the United States. (2017) (25)
Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG). (2013) (25)
Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States: Results From the National Cardiovascular Data Registry (NCDR) (2014) (24)
Diagnosis and Management of Stable Angina: A Review. (2021) (24)
Impact of moderate physical activity on the longitudinal trajectory of a cardiac specific biomarker of injury: Results from a randomized pilot study of exercise intervention. (2016) (24)
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. (2020) (24)
Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. (2004) (24)
Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. (2013) (23)
Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. (2021) (23)
A Proposal for Modest Revision of the Definition of Type 1 and Type 2 Myocardial Infarction (2019) (23)
Use of a highly sensitive assay for cardiac troponin T and N-terminal pro-brain natriuretic peptide to diagnose acute rejection in pediatric cardiac transplant recipients. (2012) (23)
Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies. (2020) (23)
Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non–ST‐Segment–Elevation Myocardial Infarction (2018) (23)
Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. (2002) (23)
Increasingly sensitive assays for cardiac troponins: a review. (2013) (22)
Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes (2017) (22)
Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease (2018) (22)
Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index (2020) (22)
Clinical characteristics, vascular function, and inflammation in women with angina in the absence of coronary atherosclerosis: the Dallas Heart Study. (2011) (22)
Antinuclear Antibodies Are Associated With All-Cause Mortality and Cardiovascular Outcomes in the General Population. (2015) (21)
Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. (2007) (21)
Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism. (2006) (21)
Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure. (2011) (21)
Determinants of Racial/Ethnic Differences in Cardiorespiratory Fitness (from the Dallas Heart Study). (2016) (20)
Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. (2013) (20)
Association of Concentric Left Ventricular Hypertrophy With Subsequent Change in Left Ventricular End-Diastolic Volume: The Dallas Heart Study (2017) (20)
Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study. (2011) (19)
Susceptibility of Cardiac Troponin Assays to Biotin Interference (2019) (19)
Association of Genetic West African Ancestry, Blood Pressure Response to Therapy, and Cardiovascular Risk Among Self-Reported Black Individuals in the Systolic Blood Pressure Reduction Intervention Trial (SPRINT). (2020) (19)
Association between low ankle-brachial index and accelerometer-derived sedentary and exercise time in the asymptomatic general population (2015) (19)
Disparities in Counseling for Lifestyle Modification Among Obese Adults: Insights from the Dallas Heart Study (2012) (18)
Free wall rupture in the elderly: deleterious effect of fibrinolytic therapy on the ageing heart. (2005) (18)
Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure (2020) (18)
Statins for acute coronary syndrome. (2014) (17)
The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial (2012) (17)
Circulating lymphotoxin β receptor and atherosclerosis: observations from the Dallas Heart Study. (2010) (17)
Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry (2018) (17)
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. (2019) (17)
Plasma dehydroepiandrosterone sulfate and cardiovascular disease risk in older men and women. (2020) (16)
Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care: Findings From the National Cardiovascular Data Registry (2019) (16)
Association of troponin T, detected with highly sensitive assay, and outcomes in infective endocarditis. (2011) (16)
Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. (2013) (16)
Predictors of reperfusion delay in patients with ST elevation myocardial infarction self-transported to the hospital (from the American Heart Association's Mission: Lifeline Program). (2014) (16)
Cardiovascular Lifetime Risk Predicts Incidence of Coronary Calcification in Individuals With Low Short‐Term Risk: The Dallas Heart Study (2014) (16)
Development and Validation of Machine Learning–Based Race-Specific Models to Predict 10-Year Risk of Heart Failure (2021) (15)
Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. (2005) (15)
Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. (2005) (15)
New-Onset Atrial Fibrillation in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Registry (2022) (15)
Circulating Interleukin-6 Levels and Incident Ischemic Stroke (2021) (15)
Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes: Results From the National Cardiovascular Data Registry (2015) (15)
Accuracy of estimating resting oxygen uptake and implications for hemodynamic assessment. (2012) (15)
The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome (2014) (14)
Differences in the inflammatory response between patients with and those without diabetes mellitus after coronary stenting. (2008) (14)
Time to Retire the BMI?: Evaluating Abdominal Adipose Tissue Imaging as Novel Cardiovascular Risk Biomarker. (2016) (14)
Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. (2021) (14)
Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR). (2016) (14)
Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study. (2009) (14)
Association of acute myocardial infarction cardiac arrest patient volume and in‐hospital mortality in the United States: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment And Intervention Outcomes Network Registry (2019) (14)
Association Between Peptidoglycan Recognition Protein-1 and Incident Atherosclerotic Cardiovascular Disease Events: The Dallas Heart Study. (2016) (14)
An evidence-based algorithm for the use of B-type natriuretic testing in acute coronary syndromes. (2010) (14)
Surrogate and clinical outcomes following ischemic postconditioning during primary percutaneous coronary intervention of ST‐Segment elevation myocardial infarction: A meta‐analysis of 15 randomized trials (2014) (14)
Prevalence and significance of detectable troponins as measured by highly sensitive assays in the general population (2013) (14)
Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. (2001) (14)
Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndromes. (2007) (14)
Lessons from the heart: troponin elevations in patients with established peripheral artery disease. (2014) (14)
ST-Segment resolution as a marker of epicardial and myocardial reperfusion after thrombolysis: insights from the TIMI 14 and in TIME-II trials. (2000) (13)
Amyloid-Beta (1-40) Peptide and Subclinical Cardiovascular Disease. (2018) (13)
Churches as targets for cardiovascular disease prevention: comparison of genes, nutrition, exercise, wellness and spiritual growth (GoodNEWS) and Dallas County populations. (2013) (13)
Effects of gender in resident evaluations and certifying examination pass rates (2019) (13)
Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction (2015) (13)
Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: From the Dallas Heart Study (2011) (12)
The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results From the National Cardiovascular Data Registry. (2015) (12)
Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. (2016) (12)
2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department: A Report of the American College of Cardiology Solution Set Oversight Committee. (2022) (12)
Defining coronary artery calcium concordance and repeatability - Implications for development and change: The Dallas Heart Study. (2017) (12)
Arrhythmias and Adaptations of the Cardiac Conduction System in Former National Football League Players (2019) (12)
Antinuclear antibodies in the general population: positive association with inflammatory and vascular biomarkers but not traditional cardiovascular risk factors. (2018) (12)
High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. (2007) (12)
Diagnostic Thresholds for Blood Pressure Measured at Home in the Context of the 2017 Hypertension Guideline: Analysis From 2 US Cohorts (2018) (11)
Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment–Elevation Myocardial Infarction: Results From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines (2017) (11)
Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial. (2021) (11)
Left hemiparesis from atrial myxoma emboli. (2003) (11)
Acute Ischemic Stroke in Patients With COVID-19 (2021) (11)
Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives. (2020) (11)
Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment (2011) (11)
Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction (2001) (10)
Addition of Highly Sensitive Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Electrocardiography for Detection of Left Ventricular Hypertrophy: Results From the Dallas Heart Study (2013) (10)
Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction (2020) (10)
Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction (2016) (10)
Separating the contenders from the pretenders: competitive high-throughput biomarker screening in large population-based studies. (2010) (10)
Association of Kidney Disease With Outcomes in COVID‐19: Results From the American Heart Association COVID‐19 Cardiovascular Disease Registry (2021) (10)
Sedentary Behavior and Subclinical Cardiac Injury: Results From the Dallas Heart Study. (2017) (10)
Effect of Doxorubicin on Myocardial Bicarbonate Production from Pyruvate Dehydrogenase in Women with Breast Cancer. (2020) (10)
Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction. (2006) (10)
Natriuretic peptides in the prognosis and management of acute coronary syndromes. (2010) (10)
Applying a Big Data Approach to Biomarker Discovery: Running Before We Walk? (2015) (10)
New tools for assessing microvascular obstruction in patients with ST elevation myocardial infarction (2004) (9)
Soluble endothelial cell‐selective adhesion molecule and incident cardiovascular events in a multiethnic population (2017) (9)
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. (2006) (9)
Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. (2005) (9)
Discordant effects of rosiglitazone on novel inflammatory biomarkers. (2013) (9)
Low levels of circulating troponin as an intermediate phenotype in the pathway to heart failure. (2012) (9)
Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19 : A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. (2021) (8)
Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (From the Atherosclerosis Risk in Communities Study). (2021) (8)
Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in a Large Urban Safety-Net Hospital. (2016) (8)
Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease? Point. (2010) (8)
Physician-Specific Practice Patterns About Discharge Readiness and Heart Failure Utilization Outcomes (2018) (8)
Biomarkers in clinical trials: can we move from fortune telling to disease profiling? (2011) (8)
Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. (2021) (8)
Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction (2015) (8)
Association of a Novel Protocol for Rapid Exclusion of Myocardial Infarction With Resource Use in a US Safety Net Hospital (2020) (8)
Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. (2021) (8)
Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction (2018) (8)
Effect of glucose-insulin-potassium infusion on plasma free fatty acid concentrations in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. (2004) (8)
Patients With Myocarditis Associated With COVID-19 Vaccination (2022) (8)
A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study. (2015) (8)
Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling (2017) (7)
Increases in Myocardial Workload Induced by Rapid Atrial Pacing Trigger Alterations in Global Metabolism (2014) (7)
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis (2022) (7)
Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults. (2021) (7)
Overriding concerns: the role of electronic medical record-based best practice alerts in reducing unnecessary laboratory testing. (2015) (7)
Clinical Relevance of the 99th Percentile Upper Reference Limit for High-Sensitivity Cardiac Troponin Assays. (2020) (7)
Separating the VAT from the FAT: new insights into the cardiometabolic risks of obesity. (2014) (7)
The skinny on fatty acid-binding protein. (2007) (7)
Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. (2020) (7)
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. (2004) (7)
What constitutes a relevant change in high-sensitivity troponin values over serial measurement? (2014) (7)
High prevalence of elevated haemoglobin A1C among adolescent blood donors: Results from a voluntary screening programme including 31,546 adolescents (2015) (7)
Association Between Sedentary Time and Coronary Artery Calcium. (2016) (7)
Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients (2016) (7)
Glycated Hemoglobin in 14,850 Adolescent Blood Donors: A Pilot Screening Program (2013) (7)
Images in cardiovascular medicine. Ebstein's anomaly associated with an anomalous coronary artery, 2 myocardial bridges, and a mahaim fiber. (1999) (6)
Aspirin, clopidogrel, or both for secondary prevention of coronary disease. (2003) (6)
Do established biomarkers such as B-type natriuretic peptide and troponin predict rejection? (2013) (6)
What Do US Physicians and Patients Think About Lipid‐Lowering Therapy and Goals of Treatment? Results From the GOULD Registry (2021) (6)
No free lunches: balancing bleeding and efficacy with ticagrelor. (2011) (6)
County-Level Social Vulnerability is Associated With In-Hospital Death and Major Adverse Cardiovascular Events in Patients Hospitalized With COVID-19: An Analysis of the American Heart Association COVID-19 Cardiovascular Disease Registry (2022) (6)
Unfavorable perceived neighborhood environment associates with less routine healthcare utilization: Data from the Dallas Heart Study (2020) (6)
B‐type Natriuretic Peptides in Acute Coronary Syndromes: Implications in an Aging Population (2012) (6)
Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers. (2010) (6)
Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial. (2011) (6)
Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. (2016) (6)
Natriuretic Peptide Hormone Measurement in Acute Coronary Syndromes (2003) (6)
Application of the new cholesterol guidelines. (2014) (6)
Target organ complications and prognostic significance of alerting reaction: analysis from the Dallas Heart Study (2016) (5)
Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial. (2003) (5)
Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. (2012) (5)
Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK (2007) (5)
Paclitaxel-eluting vs. bare metal stent implantation in saphenous vein graft lesions: Very long-term follow-up of the SOS (Stenting of Saphenous vein grafts) trial. (2015) (5)
The latest and greatest new biomarkers: which ones should we measure for risk prediction in our practice? (2006) (5)
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. (2015) (5)
N‐Terminal Pro‐B‐Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID‐19 in a Nationwide Hospitalized Cohort (2021) (5)
Combining Biomarkers and Imaging for Short‐Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults (2020) (5)
The Effect of a Disease Management Algorithm and Dedicated Postacute Coronary Syndrome Clinic on Achievement of Guideline Compliance (2008) (5)
A risk score for predicting coronary artery disease in women with angina pectoris and abnormal stress test finding. (2013) (5)
Increased cardiovascular risk associated with diabetes in Dallas County. (2006) (4)
Epidemiology and Management of ST‐Segment–Elevation Myocardial Infarction in Patients With COVID‐19: A Report From the American Heart Association COVID‐19 Cardiovascular Disease Registry (2022) (4)
Accuracy of acute myocardial infarction clinical diagnosis and its implications. (2015) (4)
The Report Card on Growth Differentiation Factor 15: Consistent Marks But Not Yet Ready for Promotion (2009) (4)
Early Repolarization Pattern Is Associated With Increased Left Ventricular Mass: Insights From the Dallas Heart Study. (2019) (4)
Screening for cardiovascular disease using B-type natriuretic peptides: detecting an imbalance of the four humours. (2005) (4)
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. (2013) (4)
Primary systemic amyloidosis presenting with advanced heart failure. (2003) (4)
Longitudinal Trajectories of Hospital Performance across Targeted Cardiovascular Conditions in the United States. (2019) (3)
Cardiorespiratory Fitness and Highly Sensitive Cardiac Troponin Levels in a Preventive Medicine Cohort (2013) (3)
Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay's Limit of Detection? (2020) (3)
The Challenges of Observational Comparative Effectiveness Research. (2020) (3)
Response by Hendren et al to Letter Regarding Article, “Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry” (2021) (3)
A life-course approach to cardiovascular disease prevention (2022) (3)
Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes (2021) (3)
Fibrinolytic Strategy for ST-Segment–Elevation Myocardial Infarction (2020) (3)
Assessing the success of fibrinolysis: can we let the interventionalist rest? (2003) (3)
Associations of cardiac injury biomarkers with risk of peripheral artery disease: The Multi-Ethnic Study of Atherosclerosis. (2021) (3)
Treatment and Outcomes of Patients With Ischemic Stroke During COVID-19 (2021) (3)
Kidney tubule health, mineral metabolism, and adverse events in persons with CKD in SPRINT. (2021) (3)
Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population. (2021) (3)
Closing the Book on Androgens and Natriuretic Peptides. (2019) (3)
Finding an effective treatment for microvascular obstruction in STEMI: a road to perdition? (2016) (3)
Keeping the genie in the bottle: growth hormone and cardiovascular disease. (2014) (3)
Validation and implementation of the fifth-generation high sensitivity Troponin T (hs-TnT) assay at a large teaching county hospital. A laboratory-driven multi-speciality effort. (2019) (3)
Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial (2022) (3)
Electrocardiographic patterns of proximal left anterior descending artery occlusion in ST-elevation myocardial infarction may be modified by 3-vessel coronary artery disease. (2012) (3)
Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus (2016) (3)
Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy. (2022) (3)
Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. (2015) (3)
Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study). (2021) (3)
Response by Jia et al to Letter Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study". (2019) (2)
Is Coronary Calcium Scanning the "Secret Sauce" for Affordable Atherosclerotic Cardiovascular Disease Primary Prevention Trials? (2021) (2)
Noninvasive assessment of reperfusion therapy: slow progress towards a worthwhile goal. (2003) (2)
Cardiac Troponins and the Future of Precision Medicine. (2016) (2)
Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥ 65 Years of Age with a Low Ejection Fraction Following Coronary Revascularization. (2020) (2)
Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. (2015) (2)
Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. (2022) (2)
HDL cholesterol efflux capacity and cardiovascular events. (2015) (2)
Acute troponin elevation and the classification of myocardial infarction. (2014) (2)
Characterization and Trajectory of Coronary Artery Calcium Percentiles: The Dallas Heart Study. (2019) (2)
Measures of adiposity and fat distribution and risk of diabetes--reply. (2013) (2)
Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry. (2022) (1)
Technology Meets Opportunity: High-Sensitivity Troponin Testing for Screening Apparently Healthy Adults. (2019) (1)
Aging and Diabetes: Shifting the Risk Trajectory With High-Sensitivity Cardiac Troponins (2020) (1)
525. Atovaquone for Treatment of COVID-19 (Ataq COVID-19) Trial (2021) (1)
American Heart Association Precision Medicine Platform Addresses Challenges in Data Sharing (2021) (1)
Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD) (2022) (1)
Antiplatelet Therapy in AMI: Combining GP IIb/IIIa Inhibition with Reduced-dose Fibrinolytic Therapy. (2001) (1)
Implementation of High-Sensitivity Cardiac Troponin Assays in the United States. (2022) (1)
Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy (2016) (1)
Exercise Training, Cardiac Biomarkers, and Cardiorespiratory Fitness in Type 2 Diabetes (2023) (1)
Response by Lewis and de Lemos to Letter Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study". (2020) (1)
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: Atherosclerosis Risk in Communities (ARIC) Study. (2023) (1)
Soluble Fms-like tyrosine kinase-1 (sFlt-1) is associated with subclinical and clinical atherosclerotic cardiovascular disease: The Dallas Heart Study. (2022) (1)
Response by de Lemos et al to Letter Regarding Article "Factors Associated With Left Atrial Remodeling in the General Population". (2017) (1)
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study (2023) (1)
High-Sensitivity Troponin after Cardiac Surgery - Is the VISION Any Clearer? (2022) (1)
Science in a Time of Crisis (2020) (1)
Is subclinical myocardial injury the smoking gun linking obesity with heart failure? (2014) (1)
Can High-Sensitivity Troponins Help to Level the Playing Field in Cardiovascular Disease Prevention between Women and Men? (2021) (1)
Rates of aldosterone antagonist use after myocardial infarction remain poor over time among guideline eligible patients. (2014) (0)
CHARACTERISTICS OF HIGH-PERFORMING HOSPITALS FOR CARDIOGENIC SHOCK FOLLOWING ACUTE MYOCARDIAL INFARCTION (2022) (0)
Recognized Outstanding Reviewers for Circulation in 2020. (2020) (0)
Small Peptide, Large Implications: Endotrophin in Heart Failure with Preserved Ejection Fraction. (2023) (0)
Lifetime obesity trends are associated with subclinical myocardial injury: The Trøndelag health study (2021) (0)
Reply: safety of same-day discharge after percutaneous coronary intervention: what is the level of evidence? (2014) (0)
Infective endocarditis. (2001) (0)
Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT (2022) (0)
Introduction to the 2020 Circulation Cardiovascular Surgery-Themed Issue. (2020) (0)
SITE-LEVEL VARIABILITY IN THE PROCESSES OF CARE OVER TIME AMONG PATIENTS WITH COVID-19 AND ELEVATED TROPONIN: INSIGHTS FROM THE AMERICAN HEART ASSOCIATION'S CVD COVID-19 REGISTRY (2022) (0)
Antiplatelet agents make a comeback in ST-elevation myocardial infarction. (2007) (0)
Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry (2023) (0)
Reply: Malignant Hypertensive Cardiomyopathy: Definition Matters. (2023) (0)
Chronic troponin elevation assessed by myocardial T1 mapping in patients with stable coronary artery disease (2023) (0)
Assays for cardiac troponins--reply. (2013) (0)
Site-level variability in the processes of care and outcomes over time among patients with COVID-19 and myocardial injury: Insights from the American Heart Association's COVID-19 Cardiovascular Disease Registry (2023) (0)
Enriching the American Heart Association COVID‐19 Cardiovascular Disease Registry Through Linkage With External Data Sources: Rationale and Design (2022) (0)
Allostatic load and the influence of economic adversity and neighborhood disadvantage on cognitive function in a multiethnic cohort (2022) (0)
Longitudinal changes in cardiac troponin and risk of heart failure among Black adults. (2022) (0)
Circulation Best Papers 2021. (2022) (0)
Recognized Outstanding Reviewers for Circulation in 2019. (2019) (0)
GOULD EDU: Primary Results of a Cluster-Randomized Trial of an Educational Intervention to Improve Guideline Adherence and Intensification of Lipid-Lowering Therapy (2022) (0)
Time in Therapeutic Range for Targeted Temperature Management and Outcomes Following Out-of-Hospital Cardiac Arrest. (2022) (0)
Letter by Neeland and de Lemos regarding article, "Rates of cardiac catheterization cancelation for ST-segment elevation myocardial infarction after activation by emergency medical services or emergency physicians: results from the North Carolina Catheterization Laboratory Activation Registry". (2012) (0)
TCT-250 Differential Intensity of Lipid-Lowering Therapy Among Patients With and Without Previous Coronary Revascularization—Insights From GOULD (2021) (0)
Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial. (2011) (0)
The use of MCP-1 and soluble CD40 ligand in a pathophysiology-guided approach to the management of coronary artery disease. (2005) (0)
Coronary artery calcium, hepatic steatosis, and atherosclerotic cardiovascular disease risk in patients with type 2 diabetes mellitus: Results from the Dallas heart study. (2023) (0)
YIA 02-04 RELATIONSHIP BETWEEN LEPTIN AND INCIDENT HYPERTENSION; OBSERVATIONS FROM THE DALLAS HEART STUDY. (2016) (0)
Recognized Outstanding Reviewers for Circulation in 2017. (2017) (0)
CORRELATION BETWEEN HOSPITAL PROCEDURAL VOLUMES AND OUTCOMES FOR TAVR AND MTEER IN THE UNITED STATES: A STS/ACC TVT REGISTRY ANALYSIS (2022) (0)
Abstract 12128: The Inflammatory Response to Percutaneous Coronary Intervention is Related to Myocardial Injury in Patients with Chronic Ischemic Heart Disease (2021) (0)
Association of Number of Live Births With Electrocardiographic and Cardiac Structural Changes (2018) (0)
YIA 02-04 RELATIONSHIP BETWEEN LEPTIN AND INCIDENT HYPERTENSION; OBSERVATIONS FROM THE DALLAS HEART STUDY (2016) (0)
Longitudinal Trends in Cardiovascular Risk Factor Profiles and Complications Among Patients Hospitalized for COVID-19 Infection: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. (2023) (0)
Relations Between Cardiac Magnetic Resonance Imaging-Derived Left Ventricular Mass, Early Repolarization, and Cardiovascular Events (from the Dallas Heart Study). (2021) (0)
B-PO02-071 NEW ONSET ATRIAL FIBRILLATION IN PATIENTS HOSPITALIZED WITH COVID-19: RESULTS FROM THE AMERICAN HEART ASSOCIATION COVID-19 CARDIOVASCULAR DISEASE REGISTRY (2021) (0)
TRENDS AND FACTORS ASSOCIATED WITH PROPHYLACTIC ANTICOAGULATION STRATEGIES IN COVID-19: AN ANALYSIS OF THE AHA COVID-19 CVD REGISTRY (2023) (0)
Keeping our eyes on the prize: low density lipoprotein cholesterol. (2009) (0)
Kidney Function Specific Reference Limits for N-terminal Pro Brain Natriuretic Peptide and High Sensitivity Troponin T: The Systolic Blood Pressure Intervention Trial (2022) (0)
Recognized Outstanding Reviewers for Circulation in 2022. (2023) (0)
Use of lipid-lowering therapies in patients with CKD and ASCVD: A 1-year update from GOULD (2021) (0)
Effects of gender in resident evaluations and certifying examination pass rates (2019) (0)
The effects of combined thrombolytic and platelet inhibitor therapy on myocardial and microvascular perfusion. (2001) (0)
Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events (2023) (0)
Associations of High‐Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With James A. De Lemos?

James A. De Lemos is affiliated with the following schools:

University of Texas Southwestern Medical Center

James A. De Lemos's Academic­Influence.com Rankings

Why Is James A. De Lemos Influential?

James A. De Lemos's Published Works

Published Works

What Schools Are Affiliated With James A. De Lemos?

James A. De Lemos's AcademicInfluence.com Rankings